We aimed to clarify the prime role of recurrence in stage I lung cancer. To determine the expression profiles, quantitative RT-PCR and real-time PCR were performed subsequently to evaluate the validity of meaningful molecules identified by 0.12 K c-DNA array experiment surveys. In all, 10 lung cancer patients presenting with recurrence of stage IB were selected and compared with 10 stage IB lung cancer patients without recurrence since biopsied 3 years previously. On c-DNA microarray data analysis using pairs of recurred and the corresponding nonrecurred patients, the following genes were found to be upregulated in the recurred cases: matrix metalloproteinase (MMP)-10 in five cases, MMP-12 in two cases, MMP-11, MMP-14, MMP-15, fos, cyclin E2, E 2 F3, TGF-a in each one case. The most frequently upregulated genes in recurred lung cancers were MMP-10 (stromelysin-2) and MMP-12 (macrophage elastase). On transcriptional assay by quantitative RT-PCR and real-time RT-PCR analysis to validate those molecules, both transcripts of MMP-10 and MMP-12 were significantly more upregulated in recurred stage IB lung cancer than in the non-recurred stage IB lung cancer (P ¼ 0.004). Transcript levels were identical to c-DNA array data. The protein levels of these entities were also evaluated by immunohistochemistry of archival slides. By immunohistochemistry, MMP-10 monoclonal antibody showed more intense immunoreactivity in the recurred stage IB lung cancer than in the nonrecurred stage IB lung cancer (P ¼ 0.0313). Our approach revealed that MMP-10 plays an important role in the recurrence in stage IB lung cancer, irrespective of the histologic type.
Introduction
The prognosis of stage I non-small-cell lung cancer (NSCLC) depends on complete surgical removal, and the 5-year survival rate is no more than 80%; the remaining patients dying succumbed to the recurrence (Martini and Beattic, 1977; Martini et al., 1995; Cai et al., 2002) . Recurrence was defined on the basis of the clinical and radiological relapse, that is, contralateral lung, lymph node, or some other organs. The aggressiveness of lung carcinoma is not always related to the tumor-node-metastasis staging. As a consequence, the validation of markers of recurrent propensity turns out to be essential in the therapeutic management. If a reliable marker could be found that could be used to predict recurrence, such patients could be administered aggressive chemotherapy that might improve the likelihood of survival.
The recurrent propensity is linked to the cell capacity of degrading basement membranes and extracellular matrix (Chambers and Matrisian, 1997; Curran and Murray, 2000; Murray, 2001) . Matrix metalloproteinases (MMPs) are believed to be the main tissue-specific physiologically relevant mediators of matrix degradation (Chambers and Matrisian, 1997; Curran and Murray, 2000; Murray, 2001) . In NSCLC, MMP-2 (gelatinase A) (Brown et al., 1993; Soini et al., 1993; Passlick et al., 2000) , MMP-9 (gelatinase B) (Brown et al., 1993; Nagakawa and Yagihashi, 1994 ) MMP-7(matrilysin) (Muller et al., 1991) , MMP-11 (stromelysin-3) (Urbanski et al., 1992; Delebecq et al., 2000; Thomas et al., 2000) , MMP-14 (MT1-MMP) (Tokuraku et al., 1995) and rarely MMP-10 (stromelysin-2) (Muller et al., 1991) have been reported to be associated with the tumor progression. The expression of some of these proteases has been correlated with the histopathological and clinical features of the tumors. The majority of studies, however, have estimated mRNA expression by RT-PCR, or mRNA in situ hybridization, or have estimated the protein activity by gelatin or casein zymography of tumor tissue homogenates, and rarely only by immunohistochemistry. Currently, the gene expression profiling technique, such as microarray, allows us to test the expression of numerous genes simultaneously and to identify genes of interest. This study aimed to identify those genes upregulated using a cDNA array including the MMP superfamily, to compare these expressions between recurred stage IB lung cancer and nonrecurred stage IB lung cancer. In an attempt to assess whether MMPs may be an indicator of recurrence and prognosis of stage I lung cancer, we quantified the expression of the candidate genes selected in c-DNA array by using quantitative RT-PCR and real-time RT-PCR and immunohistochemistry in 20 cases with NSCLC at stage I without lymph node metastasis.
This may lead to the development of novel tumor markers that will allow better prediction of clinical behavior and ultimately may discover new therapeutic approaches.
Materials and methods

Case selection
In total, 20 stage I pulmonary NSCLCs were selected from 1999 to 2001 at the tissue bank of the Department of Pathology, Yonsei University College of Medicine. All archived microscopic slides were re-examined and reclassified. Clinical records were reviewed retrospectively. The tumor stages were classified according to the international union against cancer's tumor-node-metastasis classification. Clinical parameters, such as sex, age, pathology, recurrence, diseasefree time and survival time were compared between the recurrent and nonrecurrent groups. Recurrence was defined on the basis of the clinical and radiological relapse metastasizing in the contralateral lung, lymph node, or some other organs. The work-ups for ruling out recurrence included routine CBC, SMA (13 items including liver function test, renal function test, cholesterol etc.), tumor markers (CEA, NSE, Cyfra 21), chest CT scan, whole body scan, abdominal sonography, PET, brain CT scan, or MRI every 3 or 6 months.
Messenger ribonucleic acid (mRNA) expression
Total cellular RNA was extracted from 20 fresh frozen tumor tissues. The validity of the fresh frozen tissues was checked by the examination of the corresponding tissue slides. The total RNA was prepared using Ultraspec reagent (Biotecx Lab, TX, USA) according to the manufacturer's chloroform extraction, isopropanol purification and ethanol elution protocol. The quality and integrity of mRNA extracted were confirmed using a Lab-on-a-chip and an Agilent 2100 bioanalyzer (Agilent, Palo Alto, CA, USA), and by spectrophotometry. Only six pairs of the 20 samples from recurrent and nonrecurrent patients with a 28s to 18s RNA ratio of more than 1.0 were chosen for the next procedure. The other four pairs of samples with less than 1.0 ratio of 28s to 18s RNA on lab-on-a-chip were directly skipped to RT-PCR procedure without surveillence of c-DNA array.
Construction of a microarray with hybridization
c-DNA array of 0.12 K genes (Digital Genomics, Seoul, Korea; http://www.digital-Genomics.co.kr), containing the MMP superfamily and cell-cycle-related genes, were used for the study. Total RNA (approximately 5 mg) was converted into c-DNA and labeled with aminoallyl dUTP using an amino allyl cDNA labeling kit (Ambion, Austin, TX, USA). The RNA samples from fresh-frozen tissues of recurrent lung cancer were labeled with Cy3-dUTP (Amersham), and those of nonrecurrent lung cancer with Cy5-dUTP (Amersham). The two color probes were then mixed, precipitated with ethanol, and dissolved in 45 ml DMSO (Cy dye 2.22 mM). Hybridization and washes were performed according to the manufacturer's instructions (Digital Genomics, Seoul, Korea; http://www. digital-Genomics.co.kr). Hybridization (hybridization buffer; formamide 25%, SSC 5 Â , SDS 0.1%, polyA 0.5 mg/ml, Cot-1 DNA 0.5 mg/ml) was performed in a hybridization oven at 421C for 16 h. After washing (2 Â SSC/0.1% SDS for 5 min at 421C, 0.1 Â SSC/0.1% SDS for 10 min at RT, 0.1 Â SSC for 1 min at RT), the slides were scanned with a DNA chip scanner (Scanarray lite; GSI Lumonics, Ottawa, Canada) at two wavelengths to detect emissions from both Cy3 (red) and Cy5 (green). The overall intensities were normalized using a correction coefficient obtained from the ratios of five endogenous housekeeping genes.
Differentially expressed MMP genes in the c-DNA array Six pairs of samples showing a 28s to 18s RNA ratio of more than 1.0 was chosen, and checked by lab-on-a-chip and spectrophotometry. Those samples which were proven to be adequate in the quality of mRNA (c-DNA of recurrent lung cancer labeled with Cy3-dUTP and equivalent c-DNA of nonrecurred lung cancer with Cy5-dUTP) were applied on the c-DNA array. Microarray was constructed, containing a total of 120 genes, including 27 members of the MMP superfamily, 83 cellular proto-oncogenes related to the cell cycle and 10 human and yeast internal control genes. To avoid misinterpretation of the results that could result from variation in the hybridizations, any two compared filters were normalized using five human internal control genes (ACTB, PDK2, UBC, YWHAZ, RPL13A), and a normalization coefficient calculated for each comparison was used to correct the signal intensities. Our analysis of any two hybridizations obtained from a given sample showed no difference using a ratio of 1.5 for overexpression and 0.75 for underexpression. However, the threshold values were stricter: 2.0 for overexpression and 0.5 for underexpression. In addition, if the intensity of any signal failed to be at least three times above the background value, it was discarded from our analysis.
Quantitative RT-PCR
A measure of 200 ng of RNA was transcribed to c-DNA in a final volume of 20 ml. Primers for MMP-10 and MMP-12 were selected using the ENTREZ computer-analysis package. Each primer sequence is as follows: MMP10 FW ACC TGG GCT TTA TGG AGA TAT TC, RV TCA TAT GCA GCA TCC AAA TAT GAT G and MMP12 FW GAA GCC AGA AAT CAA GTT, RV TCA AGC AAG AAT GGA CAA. Homologies with other human proteinases were excluded. The PCR products were sequenced and showed no homology with other known gene sequences. PCR was performed using the primers in a volume of 100 ml containing first-strand cDNA, primer, buffer, MgCl 2 and Taq polymerase. MMP-10 and MMP-12 were amplified using 35 cycles of the following conditions: denaturation at 941C for 60 s, annealing at 551C and 57.51C for 60 s, extension at 721C for 60 s, and a final extension of 10 min at 721C. To determine the gene expression level, b-globin was used as an internal standard in accordance with the manufacturer's (Gibco BRL) instructions. For the interpretation of electrophoresis, TINA (Raytest, Wilmington, NC, USA) software was utilized as a densitometer.
Real-time RT-PCR
TaqMan probes are designed using PrimerExpress software, Ver 2.0 (Applied Biosystems), MMP-10 (NM_002425 NCBI gene reference) ACAGGCATTTGGATTTTTCTAC TTC and MMP-12 (NM_002425 NCBI gene reference) TTCAG-GAGGCACAAACTTGTTCCTC. To normalize results, we used a VIC-labeled glyceraldehyde 3-phosphate dehydrogenase (GAPDH) TaqMan PDAR endogenous control reagent set (Applied Biosystems). Each probe was quenched by 6-carboxy-tetramethylrhodamine (TAMRA) at the 3 0 end. TaqMan PCR assays were performed on an ABI Prism 7900 HT Sequence Detection System (Perkin-Elmer Applied Biosystems). To quantify each ABC transporter gene, we prepared a master mixture containing 10 ml of 2 Â TaqMan Universal PCR Master Mix, 1 ml of gene-specific forward and 1 ml of reverse primer (each at 18 mM), 1 ml of the gene-specific probe (5 mM), and 2 ml of sterile water, and aliquoted this mixture into the wells of a 384-well optical plate. A master mixture for the endogenous control GAPDH, containing 10 ml of 2 Â TaqMan Universal PCR Master Mix, 1 ml of predeveloped TaqMan assay reagents (PDAR) from the endogenous control reagent set and 4 ml of sterile water, was treated similarly. Finally, triplicates of cDNA templates equivalent to 50 ng of RNA were added to a final volume of 20 ml. The thermal cycling conditions used were: 2 min at 501C and 10 min at 951C, followed by 45 cycles of 15 s at 951C and 1 min at 601C. Sequence Detector Software SDS 2.0 (Applied Biosystems) was used for the data analysis. From each amplification plot, a threshold cycle (Ct) value was calculated (defined as the cycle at which a statistically significant increase in DRn is first detected). The threshold was calculated automatically by SDS at the 10-fold s.d. of Rn in the first 15 cycles. The Ct values obtained were then exported to a Microsoft Excel for further analysis. We compared the expressions of each ABC transporter in the tissue panel. Therefore, for each ABC transporter, the normalized amount of expression in the tissues that showed the lowest expression was used as a calibrator and the remaining tissue samples were displayed as fold changes.
Immunohistochemistry
Pulmonary archival tissue sections (4 mm) corresponding to the fresh frozen tissues were cut from the 10 pairs of formalinfixed, paraffin-embedded tissue blocks. Three to five paraffin blocks taken from lung cancer tissue, at the same time when we prepared the tissue bank of lung cancer tissue, were used for immunohistochemistry. Sections were dewaxed in xylene, rehydrated through graded ethanol solutions, rinsed in PBS for 5 min, and immersed in 0.3% hydrogen peroxide in methanol for 30 min to block endogenous peroxidase activity. The slides were then rinsed in PBS for 5 min, blocked with a solution of 10% normal rabbit serum in PBS at room temperature for 10 min and incubated at 41C overnight with the primary monoclonal antibody of MMP-10/stromelysin-2 (NeoMarkers, Fremont, CA, USA), which contain an epitope at the hinge region of MMP-10 at a dilution ratio of 1 : 200 without any pretreatment. Nonspecific mouse immunoglobulin G1 monoclonal antibody (03001 D, PharMingen, 1 mg/ml) was used as the negative control. Tissues were incubated with biotinylated horse anti-mouse secondary antibody, at a 1 : 500 dilution (Vector Laboratories, Burlingame, CA, USA), and washed extensively with avidin-biotin peroxidase complex, at a 1 : 25 dilution. Diaminobenzene was used as the chromogen, and hematoxylin as the nuclear counterstain. Cytoplasmic immunoreactivities were classified as a continuum extending from the undetected level (0%) to diffuse and homogeneously strong staining (100%), and then recategorized into a three-tier grading system based on the percentage of tumor cells staining positively in the entire tumor boundary (0, 1: minimal o5%, 2: moderately stained o50%, 3: markedly stained 450%).
Statistical analysis
The standard w 2 test or Fisher's exact test was used for comparative analysis. The level of significance was Po0.05. The duration of the free-from-recurrence period was measured from the date of operation until the first evidence of recurrence from primary NSCLC or the last date of follow-up for patients who remained alive and with no recurrence. Survival was calculated from the date of operation until death of the date of the last follow-up. The survival rates were estimated by the Kaplan-Meier method, and the statistical analysis was performed by the log-rank test (SAS Windows).
Results
Clinical records
A total of 10 pairs of stage I lung cancer were classified as recurred or nonrecurred (Table 1 ). The primary histologic types of the recurred carcinoma were four squamous cell carcinomas, four adenocarcinomas and two other variants (one adenosquamous cell carcinoma and one large cell carcinoma), whereas the histologic types of the nonrecurred carcinoma were four squamous cell carcinomas and five adenocarcinomas and one large cell carcinoma. The recurred group manifested metastasis in the contralateral lung in four cases, with more remote metastasis, which included metastasis to the bone in three cases, liver, brain and scalene node in each one case 9 months after the initial operation. The 10 cases of nonrecurred stage I NSCLC were observed at 34.9 months on average (26.8-41.6 months). Survival time of the recurred group in the present study was 19.9 months, which was significantly lower (P ¼ 0.0021) than that of the 10 nonrecurred group (Figure 1 ).
Differential expression by cDNA microarray
In all, 10 pairs of tissue bank lung cancer tissues were used for microarray, but only six pairs of cases, including three pairs of squamous cell carcinoma, two pairs of adenocarcinomas and a pair of large cell carcinoma, were evaluated with microarray due to poor RNA sample quality. We investigated altered gene expression profiles in pairs for the 'recurred' and 'nonrecurred' stage I NSCLC. The expressions of MMP-10, MMP-11, MMP-12, MMP-14, MMP-15, MMP-16 and MMP-19 with fos, cyclin E 2 , E 2 F3 and TGF-a were upregulated in recurred stage I NSCLC as compared with the nonrecurred stage I NSCLC, MMP-10 was most frequently upregulated five out of six recurrent cases and MMP-12 was upregulated in two out of six recurrent cases. The other genes, except MMP10 or MMP12, showed an upregulated expression in only one recurred case (Figure 2 ).
Transcriptional levels of MMP-10 and MMP-12
Assessments of MMP-10 and MMP-12 transcriptional levels were available in 20 stage I NSCLC. MMP-10 mRNA (163 bp) revealed relatively stronger expression in the recurred samples than in the nonrecurred samples by quantitative RT-PCR (Figure 3) , which was highly significant (P ¼ 0.004, Wilcoxon ranked score test). However, there was no difference of MMP-10 expression according to the histologic type. MMP-12 mRNA (594 bp) was constitutively expressed, regardless of the histologic type (Figure 3) , which was not significant (P ¼ 0.269).
Expression analysis of MMP-10 and MMP-12 using real-time RT-PCR
After collecting the correct consensus sequences of all human ABC transporter mRNAs by GenBank screening, we used Primer Express Software to design the optimum specific primer and probe combinations. To construct calibration curves for relative quantification, we performed real-time amplification of several cDNA dilutions with ABC transporter genes and a reference gene. Figure 4a -c shows representative examples of MMP-10 and MMP-12. The Ct values plotted vs the log concentrations of these calibration samples showed an inverse linear correlation; the correlation coefficient for each calibrator should thus be close to one. The ratios of MMP-10 or MMP-12 to 18s mRNA was converted to a bar graph in an end point of cycles (Figure 4d ). The increased ratios of 18s mRNA of MMP-10 or MMP-12 in the recurrent group was compatible with those upregulated in cDNA array. However, there was no difference of MMP-10 expression according to the histologic type.
Immunohistochemistry MMP-10 was variably expressed in tumor cells as well as faintly expressed in normal bronchial epithelial cells. MMP-10 was relatively intense in the recurrent group as compared with the nonrecurrent group (Figure 5) , the difference of which was statistically significant (P ¼ 0.0313, Fisher's exact test). There was no difference of MMP-10 expression according to the histologic type (P ¼ 0.847). The poorer overall survival was statistically significant (P ¼ 0.0396) for cases with intense expression of MMP-10 ( Figure 6 ).
Discussion
We have explored the gene expression profiles of 10 pairs of the representative of recurred and nonrecurred stage I NSCLC, using a 0.12 K array including the MMP superfamily. We validated the expression of Figure 1 The Kaplan-Meier survival curve for 10 pairs of early lung cancer patients. The survival rate of the recurrent group was significantly lower than that of the nonrecurrent group (P ¼ 0.0021, log-rank test). X-axis means follow-up period (months) molecules upregulated in cDNA array by quantitative RT-PCR and real-time RT-PCR, and immunohistochemistry. On c-DNA expression profiles, we focused on MMP-10 and MMP-12 genes among several upregulated genes because both of them were found to be significantly upregulated in more than two cases of recurred stage I NSCLC. MMP14 and MMP15 with several proto-oncogenes, such as fos, cyclin E2, TGF-a, which were upregulated only in one case of recurred stage I NSCLC, were excluded in the current study. MMPs are believed to be the main physiologically relevant mediators of matrix degradation, and are tissue specific (Chambers and Matrisian, 1997; Curran and Murray, 2000; Murray, 2001) . Certain MMPs might predict a poor prognosis when they are overexpressed; for example, MMP-2 expression was correlated with nodal invasion (Tokuraku et al., 1995) , MMP-14 with advanced stage disease (Nawrocki et al., 1997) and TIMP-1 with poor survival (Fong et al., 1996) . Cellular localization studies by in situ hybridization and immunohistochemistry in NSCLC have been focused on MMP-2 and MMP-11 (Ohori et al., 1992; Bolon et al., 1997) . MMP-11 was found to be expressed in the stromal fibroblasts of tumors and to correlate with tumor size and nodal metastasis (Bolon et al., 1997) . We utilized a c-DNA array including almost all known MMPs and cell-cycle-related genes, in order to detect the genes most related to the recurrence of NSCLCs.
The present study suggests that MMP-10 could play an important role in the recurrence of stage I NSCLC. In addition, we found that MMP-12 could play an important role in the pathogenesis of some cases of recurred stage I NSCLC. We confirmed the overexpressions of MMP-10 and MMP-12 in recurred NSCLC by RT-PCR, by the more specific real-time RT-PCR and by immunohistochemistry. In particular, real-time RT-PCR analysis has several advantages over previous, mostly gel-based RT-PCR methods (Langmann et al., 2003) . Thus, TaqMan PCR is a closed homogenous system that does not require post-PCR processing and which has a low contamination risk. Moreover, real-time RT-PCR allows precise and reproducible quantification because it is based on Ct values rather than end-point detection, when the PCR components are rate limiting. The results obtained from the real-time RT-PCR assay are consistent with those 5) vs the recurrent samples (lane 6-11). In lanes 3 and 5, nonrecurrent cases show relatively weaker signals than those in other lanes, especially right lanes from 6-11 lanes (recurrent). MMP-12 mRNA was expressed at similar levels in recurrent and nonrecurrent samples Lanes No. 6, No. 7, No. 9, and No. 10 are squamous cell carcinomas, lanes 8 and 11 are adenocarcinomas obtained using the c-DNA array, suggesting that realtime RT-PCR offers a reliable method of quantifying ABC transporter gene expression. Ct value of real-time RT-PCR analysis was significantly increased in recurred cases, such as L6, L7, L8, L9, L10, L11, L12 and L13, as shown in Figure 4 , whereas the relative value was equivocal in RT-PCR alone.
MMP-10 (stromelysin-2), which is located on chromosome 11q22-q23, consists of a propeptide (82 amino acids), a catalytic domain (165 aa), a proline-rich 'hinge region' (25 aa) and a C-terminal domain (188 aa) (Nagase, 1998) . The biological role of MMP10 has been little studied, but it is suggested to be linked with reproduction, such as endometrial shedding during menstruation, and wound healing (Nagase, 1998; Rechardt et al., 2000) . Although the exact role of MMP-10 in tumor progression is not clearly understood, transformed rat embryo cell lines with high metastatic potential were found to produce higher levels of MMP-10 than nonmetastatic lines (Sreenath et al., 1992) . These studies suggest a correlation between invasive behavior of tumor cells and the expression of stromelysins. In terms of tumor invasion and metastasis, a few malignant tumors including head and neck carcinoma and lung cancer (Muller et al., 1991) , and skin cancer (Kerkela et al., 2001) , express MMP-10 along with MMP-1 and MMP-7.
MMP-12 (macrophage elastase) incorporates the principal cellular source of this enzyme and it is able to degrade insoluble elastin (Shapiro and Senior, 1998) . Since macrophages can express several elastolytic proteinases other than macrophage elastase, that is, cystein proteinases, metalloproteinases, particularly MMP-9, MMP-7 and perhaps MMP-3 (Shapiro and Senior, 1998), MMP-12 most closely resembles the stromelysins MMP-3, MMP-10 and matrilysin (MMP-7), with respect to their ability to hydrolyse a broad variety of extracellular matrix components (Shapiro and Senior, 1998) . MMP-12 is unique with respect to its predominantly macrophage-specific pattern of expression and perhaps its ability to readily shed its C-terminal domain on processing (Nagase, 1998; Shapiro and Senior, 1998) . Recently, MMP-12 has been shown to play a central role in the pathogenesis of pulmonary emphysema (Hautamaki et al., 1997) and of atherosclerotic lesions (Carmeleit et al., 1997) . The molecular bases for the MMP-12 expressions of macrophages are unknown.
We conclude that MMP-10 is mainly upregulated during the process of recurrence of stage I NSCLC at the transcriptional and protein level. Furthermore, the determination of MMP-10 may provide a clue to the preselection of patients with lung cancer in clinical trials to investigate the benefits of MMP-inhibitory therapy.
